Trade Summary

6 days ago, Farzan Nima, serving as Dir at Keros Therapeutics, Inc. (KROS), sold 2,625 shares at $10.73 per share, for a total transaction value of $28,166.25. Following this transaction, Farzan Nima now holds 9,767 shares of KROS.

This sale represents a 21.18% decrease in Farzan Nima's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, June 4, 2026 and publicly disclosed via SEC Form 4 filing on Monday, June 8, 2026 at 4:37 PM ET, 4 days after the trade was made.

Keros Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.